预防医学2024,Vol.36Issue(6) :536-539.DOI:10.19485/j.cnki.issn2096-5087.2024.06.018

2012-2022年罗湖区肺结核患者利福平和异烟肼耐药分析

Rifampicin and isoniazid resistance among pulmonary tuberculosis patients in Luohu District from 2012 to 2022

唐小芬 秦道新 金凤霞 田园 邹永霞 沈玉蓉 刘瑶 谢秀钗
预防医学2024,Vol.36Issue(6) :536-539.DOI:10.19485/j.cnki.issn2096-5087.2024.06.018

2012-2022年罗湖区肺结核患者利福平和异烟肼耐药分析

Rifampicin and isoniazid resistance among pulmonary tuberculosis patients in Luohu District from 2012 to 2022

唐小芬 1秦道新 1金凤霞 1田园 1邹永霞 1沈玉蓉 1刘瑶 1谢秀钗1
扫码查看

作者信息

  • 1. 深圳市罗湖区慢性病防治院,广东 深圳 518020
  • 折叠

摘要

目的 了解2012-2022年广东省深圳市罗湖区肺结核患者利福平和异烟肼耐药情况及变化趋势,为耐药结核病的防控提供依据.方法 通过中国疾病预防控制信息系统结核病监测报告管理系统收集2012-2022年罗湖区病原学检测阳性的肺结核患者的基本信息、治疗分类和耐药情况等资料,描述性分析利福平和异烟肼耐药率及变化趋势.结果 纳入肺结核患者2 126例,年龄M(QR)为34(25)岁.男性1 334例,占62.75%;女性792例,占37.25%.2012-2022年罗湖区耐药肺结核患者302例,耐药率为14.21%,其中单耐利福平患者60例,耐药率为2.82%;单耐异烟肼患者113例,耐药率为5.32%;耐多药患者129例,耐多药率为6.07%.2012-2022年单利福平耐药率呈下降趋势(P<0.05),耐多药率呈上升趋势(P<0.05),单异烟肼耐药率无明显变化趋势(P>0.05).非深圳市户籍患者耐多药率高于深圳市户籍患者;复治患者单利福平耐药率、耐多药率高于初治患者(均P<0.05).结论 2012-2022年罗湖区肺结核患者单利福平耐药率呈下降趋势,耐多药率呈上升趋势.应重点关注非深圳市户籍和复治的肺结核患者.

Abstract

Objective To investigate the resistance to rifampicin and isoniazid and the changing trends among patients with pulmonary tuberculosis in Luohu District,Shenzhen City,Guangdong Province from 2012 to 2022,so as to provide insights into improving drug-resistant pulmonary tuberculosis control and prevention strategies.Methods Basic informa-tion,treatment classification and drug resistance data of patients with pulmonary tuberculosis and positive pathogenic de-tection in Luohu District from 2012 to 2022 were collected through the Tuberculosis Surveillance System of Chinese Dis-ease Prevention and Control Information System,and resistance rates of rifampicin and isoniazid and the changing trends were analyzed.Results A total of 2 126 patients with pulmonary tuberculosis were collected and had a median age of 34(interquartile range,25)years,including 1 334 males(62.75%)and 792 females(37.25%).There were 302 patients with drug-resistance in Luohu District from 2012 to 2022,with a resistance rate of 14.21%.Among them,60 patients were monoresistant to rifampicin(2.82%),113 patients were monoresistant to isoniazid(5.32%),and 129 pa-tients were multidrug resistant(6.07%).The rate of rifampicin monoresistance showed a downward trend from 2012 to 2022,while the rate of multidrug resistance showed an upward trend(both P<0.05).There was no significant tendency in the rate of isoniazid monoresistance(P>0.05).The rate of multidrug resistance among patients without Shenzhen resi-dence was higher than that among patients with Shenzhen residence;the rates of rifampicin resistance and multidrug re-sistance among retreated patients were higher than those among treatment-naïve patients(all P<0.05).Conclusions The rate of rifampicin monoresistance appeared a downward trend and the rate of multidrug resistance appeared an up-ward trend among patients with pulmonary tuberculosis in Luohu District from 2012 to 2022.Attention should be given to non-Shenzhen residence and retreated patients.

关键词

肺结核/利福平/异烟肼/耐药/耐多药

Key words

pulmonary tuberculosis/rifampicin/isoniazid/drug resistance/multidrug resistance

引用本文复制引用

出版年

2024
预防医学
浙江省预防医学会

预防医学

CSTPCD
影响因子:1.002
ISSN:2096-5087
参考文献量7
段落导航相关论文